U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07296263) titled 'Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems' on Dec. 17.
Brief Summary: This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain. The study will enroll adult patients with known or suspected brain lesions involving blood-brain barrier disruption. Each participant will undergo a pre-contrast pMRI scan, receive an intravenous GBCA injection, and then complete a post-contrast pMRI scan using the Swoop(R) Portable MR Imaging(R) System. Lesi...